- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03700892
In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense (Cinimic)
Study Overview
Status
Intervention / Treatment
Detailed Description
Investigators will evaluate the acute effect of CA-flavored e-cigs on MCC and IS immune cells in up to 32 healthy, young adults who are current e-cig users with a total of less than 10 pack-years cigarette smoking history. MCC will be measured by gamma scintigraphy at baseline and following controlled vaping of e-liquids with and without cinnamon flavoring. Two different e-liquids (one completely devoid and one containing at least 30 mM CA similar to "Hot Cinnamon Candies" which is commercially available) will be used for two separate randomized vaping sessions.
The randomization scheme for the two different e-liquids (e-liquids with and without CA) will be generated by using the Web site Randomization.com (http://www.randomization.com), assigned treatment Regimen A and B by an assigned study team member, and provided to the study team. This individual will also be responsible for loading the e-cigarette with the appropriate solution for that session prior to the vaping sessions.
Participants will undergo baseline testing during the screening visit, which will occur 2-3 weeks prior to the first controlled vaping session. Investigators will also recruit non-vaping control subjects (n=32), who will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group. will aim to recruit similar numbers of males and females in both cohorts. While investigators cannot guarantee age-matching and sex-matching in these cohorts, based on our previous studies, investigators do not expect to find significant age and sex differences in the two cohort. In addition, potential confounders, such as age, sex, and BMI will be included as covariates in our multivariate analysis.
Observations obtained from the non-vaping control group will provide necessary information on potential baseline differences in the two cohorts (i.e. current vapers versus non-vaping controls). These data from the non-vaping control group are important to provide a reference for any potential CA-induced changes in the vaping group. Hence, there are two stages of the study:
Stage 1. A cross sectional observational cohort comparison of baseline MCC and IS immune cells in a reference cohort of n=32 non-vaping control subjects and E-cig cohort of n=32 currently vaping subjects (confounding based on other variables such as BMI, sex, age is possible for this stage).
Stage 2. A randomized comparison of changes in MCC and IS immune cells after Regimen A (e-cig us without CA) and Regimen B (e-cig use with CA). The cohort of e-cig users will undergo a randomized 2-treatment, 2-period, 2-sequence crossover study of CA exposure.
For stage 1, baseline measurements of Tc99m-SC clearance will be used to measure each subject's normal baseline MCC and IS immune cell characteristics. For both stages, subjects will be asked to complete a vaping diary to record information on the device and e-liquids (name/vendor/e-liquids/puffs/device settings) used during their normal vaping sessions for the entire duration of the study. In addition, for stage 2, participants will be asked to maintain their current habits for the duration of the study, not to significantly increase or decrease their vaping patterns, including the nicotine concentrations of their e-liquids.
For stage 2, for each e-cig vaping session (Training and MCC Test Days), subjects will be asked to follow a laboratory-based protocol involving 6, 5-minute paced vaping segments (1 puff/minute) over a 1 hour time period, vaping the e-liquid with and without CA provided by us. On each Test Day, participants will undergo the vaping protocol immediately prior to inhalation of the Tc99m-SC (10 min between end of vaping and inhalation of Tc99m-SC). An initial deposition scan of Tc99m-SC will then be obtained followed by dynamic imaging of the lung with subjects seated in front of the gamma camera to determine potential changes in MCC induced by acute exposure to CA-flavored e- cigarettes. Induced sputum samples will be collected at baseline, and after each MCC scan.
24 hours after completion of the MCC scans. The two randomized vaping sessions will be separated by 2-3 weeks. While there are no data providing specific information on the duration needed to washout the effects of CA on MCC, previous studies examining changes in MCC following inhalation of other aerosols have shown that this washout period is sufficient to prevent potential carryover between the two treatments.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7310
- UNC Center for Environmental Medicine, Asthma and Lung Biology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- An equal number of participants who currently use a vaping device and those who do not use a vaping device
- Age 18-40
- Must have a Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV₁) of at least 80% of predicted. Participants who fall out of the normal range will be offered a copy of the test to share with their personal physician.
Exclusion Criteria:
- Any pre-existing lung disease (asthma, cystic fibrosis, etc.)
- Any significant chronic illness, such as, but not limited to, heart disease, uncontrolled hypertension, diabetes, auto-immune disease
- Any use of tobacco products (other than e-cig) in the past 3 months, or a greater than 10 pack year history of smoking cigarettes
- Pregnant or nursing women
- Participants with a history of radiation exposure in the past year which exceeds annual safe limits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cinnamaldehyde, then PG/VG
Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
A 2-3 week washout period will follow.
Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
|
Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Other Names:
Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Other Names:
|
EXPERIMENTAL: PG/VG, then Cinnamaldehyde
Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
A 2-3 week washout period will follow.
Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
|
Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Other Names:
Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Other Names:
|
NO_INTERVENTION: Healthy Controls
Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CA-induced Changes in Whole Lung MCC
Time Frame: Through study completion, an average of three months
|
Absolute values of whole lung MCC at baseline compared to after CA vaping session.
Absolute repeat values of Whole lung MCC = average % mucus cleared from the whole lung over a 90-minute period.
|
Through study completion, an average of three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CA-induced Changes in Regional Lung MCC
Time Frame: Through study completion, an average of three months
|
Absolute repeat values of Central and Peripheral lung MCC = average % mucus cleared from the Central and Peripheral lung over a 90-minute period.
This will assess clearance rates from the central (C) and peripheral (P) regions as secondary endpoints that may reflect differential effects between a region with relatively more (C) vs. less (P) large bronchial airways.
|
Through study completion, an average of three months
|
Percent Polymorphonuclear Leukocytes (PMN) in Induced Sputum
Time Frame: Through study completion, an average of three months
|
Percent change of PMNs in vapers from baseline compared to post CA vaping session.
Percent change in PMNs in vapers from baseline compared to post PG/VG vaping session are included as an additional comparison.
|
Through study completion, an average of three months
|
Absolute Values of Whole Lung MCC for Each Group
Time Frame: Start of study, up to three months
|
Baseline Differences in Whole lung MCC clearance rates in Non-smokers/Non-vapers as Compared to E-cigarette Users.
Absolute group values of Whole Lung MCC =average % mucus cleared from the whole lung over a 90-minute period.
|
Start of study, up to three months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CA-Induced Changes in Immune Cell Function
Time Frame: Through study completion, an average of three months
|
Percent change from baseline in phagocytosis
|
Through study completion, an average of three months
|
Peripheral Blood Mononuclear Cell Analysis
Time Frame: Through study completion, an average of three months
|
Percent change in cell counts as compared to baseline
|
Through study completion, an average of three months
|
Blood Serum Analysis of Inflammatory Mediators
Time Frame: Through study completion, an average of three months
|
Percent change of mediator expression as compared to baseline
|
Through study completion, an average of three months
|
CA-Induced Changes in Epithelial Lining Fluid
Time Frame: Through study completion, an average of three months
|
Pre-vaping session versus post-vaping session expressed as a percent change
|
Through study completion, an average of three months
|
CA-Induced Changes in Epithelial Lining Fluid 24 Hours After Vaping Session
Time Frame: Through study completion, an average of three months
|
Percent change as compared to post-vaping session sample
|
Through study completion, an average of three months
|
Changes in Epithelial Lining Fluid
Time Frame: Through study completion, an average of three months
|
Percent change as compared to baseline
|
Through study completion, an average of three months
|
Tidal Volume Subjects Own E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Tidal Volume in milliliters
|
Through study completion, an average of three months
|
Respiratory Rate With Subjects Own E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Respiratory Rate in breaths per minute
|
Through study completion, an average of three months
|
Minute Ventilation With Subjects Own E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Minute Ventilation in L/min
|
Through study completion, an average of three months
|
Inspiratory Flow With Subjects Own E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Inspiratory flow in L/min
|
Through study completion, an average of three months
|
Expiratory Flow With Subjects Own E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Expiratory flow in L/min
|
Through study completion, an average of three months
|
Tidal Volume With Investigator E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Tidal Volume in milliliters
|
Through study completion, an average of three months
|
Respiratory Rate With Investigator E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Respiratory Rate in breaths per minute
|
Through study completion, an average of three months
|
Minute Ventilation With Investigator E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Minute Ventilation in L/min
|
Through study completion, an average of three months
|
Inspiratory Flow With Investigator E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Inspiratory flow in L/min
|
Through study completion, an average of three months
|
Expiratory Flow With Investigator E-cigarette Device
Time Frame: Through study completion, an average of three months
|
Expiratory flow in L/min
|
Through study completion, an average of three months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ilona Jaspers, PhD, University of North Carolina
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-2275
- R01HL139369 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata
Requests for access to individual participant data should be sent to bring44@email.unc.edu or carole.robinette@med.unc.edu. Access will be granted after a data access agreement has been signed with UNC.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on Cinnamaldehyde e-liquid
-
American University of Beirut Medical CenterNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)RecruitingNicotine Dependence | Nicotine Vaping | Nicotine AddictionLebanon
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruitingCigarette Smoking | Sex Differences | Nicotine Addiction | E-Cig Use
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | VapingUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruitingNicotine Use Disorder
-
University of Southern CaliforniaCompletedElectronic Cigarette Use | Cigarette Smoking | Cigarette Use, Electronic | E-Cig UseUnited States
-
University of California, DavisCompleted
-
Prof. Dominique de Quervain, MDCompleted
-
Virginia Commonwealth UniversityU.S. Department of JusticeCompleted
-
Cedars-Sinai Medical CenterTerminatedCoronary Artery Disease | Myocardial PerfusionUnited States